A-Alpha Bio

Boosts Performance of Protein-Protein Interaction Prediction Using NVIDIA BioNeMo on AWS

A-Alpha Bio, a biotechnology startup, faced challenges in efficiently predicting protein-protein interactions, which are crucial for drug discovery and development. To address this, the organization leveraged NVIDIA BioNeMo on AWS, significantly enhancing their computational capabilities. This approach led to a remarkable 12-fold increase in the throughput of protein-binding predictions, allowing them to process over 108 million inference calls—10 times their initial projection. As a result, A-Alpha Bio improved the quality of their candidate selections and accelerated the protein design process, reducing the number of experimental cycles by 1 to 2, ultimately lowering costs and expediting research and development efforts.

This case study is in our research queue. We publish each one with the outcomes and the sources behind them, which takes time — check back, or read the ones that are ready.